CABA Stock Forecast: Cabaletta Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.94
−7.00% on the day

The median 12-month analyst price target for Cabaletta Bio, Inc. is $14. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$217.9M
Ticker Nerd rank
28/ 100
Median analyst target
$14
Analysts covering
10
Revenue$0.0
Operating income−$52.0M
Net income−$51.0M
Free cash flow−$41.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−26.6%
1M
−41.7%
YTD
−57.1%
1Y
−56.3%
From 52W high
−77.4%
From 52W low
0.0%
$0.94
$4.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Cabaletta Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
28/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
64
Growth
63
Accruals
42
Issuance
35
Volatility
30
Momentum
25
Quality
24
Value
14

Revisions (64): Analysts have, on balance, been raising their forecasts.

Value (14): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CABA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CABA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26CABAHigh $20Median $14Low $3

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8
Buy
2
Hold
0
Sell
$3
Low
$14
Median
$20
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
9 Nov 2026CitigroupMaintainsBuy$10 → $8.00
1 Sept 2026HC Wainwright & Co.ReiteratesBuy$16
14 Aug 2026Wells FargoMaintainsEqual-Weight$4.00 → $3.00
15 May 2026Wells FargoMaintainsEqual-Weight$2.00 → $4.00
4 May 2026Cantor FitzgeraldReiteratesOverweight—
24 Mar 2026GuggenheimMaintainsBuy—
24 Mar 2026Morgan StanleyMaintainsOverweight—
31 Oct 2025Cantor FitzgeraldMaintainsOverweight—
10 Oct 2025HC Wainwright & Co.ReiteratesBuy—
5 Sept 2025Cantor FitzgeraldReiteratesOverweight—
14 Aug 2025CitigroupMaintainsBuy—
8 Aug 2025GuggenheimMaintainsBuy—
8 Aug 2025Wells FargoMaintainsEqual-Weight—
11 June 2025HC Wainwright & Co.ReiteratesBuy—
16 May 2025CitigroupMaintainsBuy—
16 May 2025GuggenheimMaintainsBuy—
15 May 2025GuggenheimMaintainsBuy—
1 Apr 2025GuggenheimReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CABA.

Market Radar

This page is one stock. Monday covers all of them.

CABA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CABA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Cabaletta Bio, Inc. returned −56.3% against +6.9% for the S&P 500, dividends included.

CABA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26CABAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CABA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−89.5%

Higher than 15% of US stocks

Return on assets
−46.0%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cabaletta Bio, Inc. has a market value of $217.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$181.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$154.2M.

  • Shares outstanding: 167.7M.

  • Cabaletta Bio, Inc. employs 154 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CABA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CABACabaletta Bio, Inc.$217.9M28
FTHFaeth Therapeutics, Inc.$203.1M26
VNDAVanda Pharmaceuticals, Inc.$203.6M72
DTILPrecision BioSciences, Inc.$204.3M81
DRUGBright Minds Biosciences, Inc.$198.5M17
ACIUAC Immune SA$198.5M66
NGENNervGen Pharma Corp.$198.4M33

Take a look at CABA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Cabaletta Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CABA

What is the CABA stock price forecast for 2026-2027?

The median 12-month analyst price target for Cabaletta Bio, Inc. is $14, with estimates ranging from $3 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CABA stock a buy right now?

Of the 10 analysts covering Cabaletta Bio, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cabaletta Bio, Inc. 28 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CABA?

As at 21 Nov 2026, Cabaletta Bio, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (64 of 100).

Will CABA stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts is $14, and Ticker Nerd's factor model ranks Cabaletta Bio, Inc. 28 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CABA stock forecast for 2030?

No analyst covering Cabaletta Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CABA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $20 over the next 12 months.

How has CABA stock performed over the past year?

Cabaletta Bio, Inc. returned -56.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cabaletta Bio, Inc. do?

Cabaletta Bio Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. The company’s current programs center on targeted cell therapies designed to selectively eliminate disease-causing B cells while sparing healthy immune function.

Company

About Cabaletta Bio, Inc.

Cabaletta Bio Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. The company’s current programs center on targeted cell therapies designed to selectively eliminate disease-causing B cells while sparing healthy immune function. Its lead candidate, rese-cel, is being studied in the RESET clinical development program across autoimmune conditions including lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Cabaletta Bio also advances CAAR T cell approaches through its broader CABA platform, which is intended to address B cell–mediated autoimmune disorders. Based in Philadelphia, Cabaletta Bio plays a specialized role in the cell therapy market by focusing on precision immunology and disease-modifying treatments for patients with severe autoimmune disease.

CEO Dr. Steven A. Nichtberger M.D. · 154 employees · United States · https://www.cabalettabio.com